RT Journal Article
SR Electronic
T1 The muscarinic M1-receptor-selective antagonist, telenzepine, had no bronchodilatory effects in COPD patients
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 378
OP 382
DO 10.1183/09031936.93.06030378
VO 6
IS 3
A1 D Ukena
A1 C Wehinger
A1 R Engelstatter
A1 V Steinijans
A1 GW Sybrecht
YR 1993
UL http://erj.ersjournals.com/content/6/3/378.abstract
AB In a double-blind, placebo-controlled, randomized, cross-over trial, we studied the effects of the muscarinic M1-receptor-selective antagonist (+/-)-telenzepine (3 mg orally at 6 p.m. for 5 days) in 21 patients with chronic obstructive pulmonary disease (COPD). At enrollment all patients showed at least a 50% decrease in airway resistance (Raw) after inhalation of 400 micrograms fenoterol or 200 micrograms oxitropium bromide. Telenzepine did not have a significant effect on forced expiratory volume in one second (FEV1) or forced vital capacity (FVC). Also, no significant changes could be detected in daily spirometric profiles or Raw. The results indicate that short-term treatment with the M1-selective antagonist, telenzepine, does not improve airway function in COPD patients, at least after administration by the oral route.